We found that high levels of several immune-checkpoint molecules, including CTLA-4, PD-1, PD-L1/2, LAG3, IDO1, CD73, and CD39 are associated with an increased cytolytic index, across many cancers; and we expect that a combinatorial targeting of such immune-checkpoint molecules can provide a synergistic effect in cancer immunotherapy. Here, CD274 is linked to cancer.